Method for treating diabetes and other glucose regulation disorders using stem cells
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11077146-B2
Publication Date
2021-08-03
Expiration Date
Abstract
Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.
Core Innovation
The disclosed invention relates to a method for generating stem cell-derived hormone producing-cells (SCDHPC) for treating diabetes and glucose regulation disorders. The method obtains gastro-intestinal hormone producing cells from a donor and obtains stem cells from a patient, and then culturing the donor gastro-intestinal hormone producing cells in the presence of the patient stem cells under conditions such that the stem cells differentiate into SCDHPC.
The SCDHPC are incretin-producing cells, and the gastro-intestinal hormone is an incretin. In the disclosed approach, the differentiated SCDHPC, when introduced into the patient, cause a lowering of the patient’s blood glucose level after the ingestion of food to euglycemic levels.
The disclosure frames the incretin-producing cells as stem cell-derived L-cells (SCDLC) that secrete GLP-1 and/or stem cell-derived K-cells (SCDKC) that secrete GIP, with these hormones being used to improve blood glucose control. The disclosure also identifies stem cell sources/types including bone marrow stem cells, mesenchymal stem cells (MSC), and induced pluripotent stem cells (iPSCs), and emphasizes differentiation/quality criteria intended to reduce teratoma risk by limiting pluripotent behavior.
Claims Coverage
The partial content provides two independent claims (clm-00001 and clm-00018). Across these independent claims, the core inventive subject matter includes generating stem cell-derived hormone producing-cells by culturing donor gastro-intestinal hormone producing cells with patient stem cells, where the resulting SCDHPC are incretin-producing cells that lower blood glucose after food ingestion or maintain euglycemic blood glucose for an extended period. A total of four main inventive features are captured at the independent-claim level from the provided text, with additional refinements described in dependent claims.
Donor gastro-intestinal hormone producing cells with patient stem cells to generate SCDHPC
Obtaining gastro-intestinal hormone producing cells from a donor; obtaining stem cells from a patient; and culturing the gastro-intestinal hormone producing cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived hormone producing-cells (SCDHPC).
Food ingestion associated lowering of blood glucose after introducing SCDHPC
Wherein the SCDHPC, when introduced into the patient, cause a lowering of the patient’s blood glucose level after the ingestion of food.
Extended maintenance of euglycemic blood glucose by introduced SCDHPC
Wherein the SCDHPC, when introduced into the patient, maintain the patient’s blood glucose levels within euglycemic levels for an extended period.
Incretin-producing gastro-intestinal hormone producing cells
Wherein the gastro-intestinal hormone producing cells are incretin-producing cells and wherein the gastro-intestinal hormone is an incretin.
The independent claims cover generating SCDHPC by culturing donor gastro-intestinal hormone producing cells with patient stem cells so the cells differentiate into incretin-producing SCDHPC, which are introduced into the patient to either lower blood glucose after food ingestion or maintain euglycemic blood glucose for an extended period.
Stated Advantages
Lowering the patient's blood glucose level after the ingestion of food.
Maintaining the patient's blood glucose levels within euglycemic levels for an extended period.
Documented Applications
Treating diabetes and glucose regulation disorders by generating SCDHPC that regulate blood glucose in a human.
Improving post-ingestion glycemic control by lowering blood glucose to euglycemic levels after food ingestion.
Interested in licensing this patent?